Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)

This publication has 21 references indexed in Scilit:

• The global burden of cancer
  Seminars in Cancer Biology, 1998
• Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183
  Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1998
• Antiangiogenesis for cancer therapy
  The Lancet, 1997
• Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
  Published by Elsevier ,1996
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
  Nature Medicine, 1995
• High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
  Cell, 1993
• The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
  Science, 1992
• What Is the Evidence That Tumors Are Angiogenesis Dependent?
  JNCI Journal of the National Cancer Institute, 1990
• Induction of angiogenesis during the transition from hyperplasia to neoplasia
  Nature, 1989
• Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
  Journal of Clinical Oncology, 1986